Cash Flow Statement

Amortization Amortization Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Avricore Health (AVCRF) Gains from Sales and Divestitures (2024)

Avricore Health has reported Gains from Sales and Divestitures over the past 1 years, most recently at -$22930.8 for Q4 2024.

Quarterly Gains from Sales and Divestitures changed N/A to -$22930.8 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$22930.8 through Dec 2024, changed N/A year-over-year, with the annual reading at -$23396.9 for FY2024, N/A changed from the prior year.
Gains from Sales and Divestitures was -$22930.8 for Q4 2024 at Avricore Health.
Over five years, Gains from Sales and Divestitures peaked at -$22930.8 in Q4 2024 and troughed at -$22930.8 in Q4 2024.